Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands
BackgroundThe phase 3 clinical trial KEYNOTE-426 suggested a higher efficacy regarding overall survival (OS) and progression-free survival (PFS) of pembrolizumab+axitinib compared to sunitinib as a first-line treatment for patients with advanced renal cell carcinoma. In this analysis, the potential cost-effectiveness of this combination treatment versus sunitinib for patients with advanced clear-cell renal cell carcinoma (accRCC) was examined from the societal perspective in the Netherlands.MethodsFor this analysis, a partitioned survival model was constructed. Clinical data were obtained from... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2023 |
Reihe/Periodikum: | Frontiers in Oncology, Vol 13 (2023) |
Verlag/Hrsg.: |
Frontiers Media S.A.
|
Schlagwörter: | cost-effectiveness / budget impact / pembrolizumab / axitinib / sunitinib / renal cell carcinoma / Neoplasms. Tumors. Oncology. Including cancer and carcinogens / RC254-282 |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-29172770 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doi.org/10.3389/fonc.2023.1205700 |